GPBAR1 and fatty liver disease: On the other hand, TGR5 agonists have been shown to decrease liver steatosis and associated hepatocyte damage, as evidenced by reductions in plasma liver enzymes LDH, ASAT, and ALAT in an HFD mouse model [112].